8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

_____________________

FORM 8-K

_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 18, 2011

_____________________

ORAMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 000-50298 (Commission File Number) 98-0376008 (IRS Employer Identification No.)

Hi-Tech Park 2/5 Givat Ram

PO Box 39098

Jerusalem, Israel 91390

 (Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: 972-2-566-0001

_____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

ITEM 7.01         REGULATION FD DISCLOSURE

On May 18, 2011, Oramed Pharmaceuticals Inc. issued a press release announcing that it was chosen to present at The 1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Shanghai, China. The presentation will be given by Roy Eldor M.D., Director of Medical Affairs at Oramed, on Friday June 3, 2011 at 10:30 AM – 12:00 PM in Hall A at the exhibition center.

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

ITEM 9.01         FINANCIAL STATEMENTS AND EXHIBITS.

(d)           Exhibits

Exhibit Number	Description
99.1	Press Release dated May 18, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

	ORAMED PHARMACEUTICALS INC.
Dated: May 18, 2011
	By:	/s/ Nadav Kidron
		Nadav Kidron
		President, CEO and Director

Exhibit Index

Exhibit Number	Description
99.1	Press Release dated May 18, 2011

EX-99.1

Oramed Pharmaceuticals to Present at The 1st Asia Pacific Congress

on Controversies to Consensus in Diabetes, Obesity and

Hypertension (CHODy), China 2011

Oramed to Present on Friday June 3, 2011

JERUSALEM, Israel – May 18, 2011 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (www.oramed.com), a developer of oral delivery systems, announced today that it was chosen to present at The 1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Shanghai, China.  The presentation will be given by Roy Eldor M.D., Director of Medical Affairs at Oramed, on Friday June 3, 2011 at 10:30 AM – 12:00 PM in Hall A at the exhibition center.  

Event:The 1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension

Date: Friday June 3, 2011

Time: 10:30 AM – 12:00 PM

For more information about the upcoming conference, please visit the following website: http://www.codhy.com/AP/2011/en-US/Default.aspx

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.  

For more information, please visit www.oramed.com

Forward-looking statements 

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements. 

Company and Investor Relations Contact:

Oramed Pharmaceuticals

Tara Horn

USA: +1 646-240-4193

Int'l: + 972-54-334-4318

Email: tara@oramed.com